Filing Details
- Accession Number:
- 0001104659-24-099838
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-13 16:35:19
- Reporting Period:
- 2024-09-11
- Accepted Time:
- 2024-09-13 16:35:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1377121 | Protagonist Therapeutics Inc | PTGX | Pharmaceutical Preparations (2834) | 980505495 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1921163 | Asif Ali | C/O Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark CA 94560-1160 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-09-11 | 2,203 | $44.59 | 34,960 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-09-11 | 6,000 | $19.19 | 40,960 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2024-09-11 | 6,000 | $12.17 | 46,960 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-09-11 | 12,000 | $44.47 | 34,960 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-09-11 | 6,000 | $0.00 | 6,000 | $19.19 |
Common Stock | Stock Option (right to buy) | Disposition | 2024-09-11 | 6,000 | $0.00 | 6,000 | $12.17 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
76,500 | 2032-04-18 | No | 4 | M | Direct | |
45,750 | 2033-01-15 | No | 4 | M | Direct |
Footnotes
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.43 to $44.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.
- The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.